A systematic review and economic model of the effectiveness and ...

More documents

Recommendations

Info

24 TABLE 5 Clinical effectiveness MPH medium dose (15–30 mg/day) versus placebo Study Design Intervention – N Age Duration Core outcomes (years) (weeks) C (5×) MPH (20 mg/day, o.d.) – 45 5–12 5 Core: no hyp; ACTeRS: total score QoL: not reported AE: not reported Administered once daily Rapport, 1989 85 C (5×) MPH (20 mg/day, o.d.) – 31 6–11 6 Core: no hyp; ACTeRS: total score QoL: not reported AE: not reported DuPaul, 1993 49 Administered two or more times daily Conners, 1980 46 P MPH (22.0 mg/day, b.d.) – 60 6–11 8 Core: Conners’ Parent Questionnaire: hyperactivity; Conners’ Teacher Questionnaire: hyperactivity QoL: no CGI; parent global judgements of improvement AE: Physician’s Rating Sheet for Side Effects Standardised Form: 50-item checklist (parents); weight P MPH (20.08 mg/day, b.d.) – 40 5.7–13.1 3 months Core: CPRS: hyperactivity index; ACTeRs: hyperactivity QoL: not reported AE: not reported Brown, 1986 42 C (4×) MPH (25.1 mg/day, b.d.) – 11 13–15 8 Core: CPRS-R: Hyperactivity Index; Conners’ Teacher Hyperactivity Index; ACTeRS: hyperactivity QoL: not reported AE: SERS (parents); weight Brown, 1988 43 C (3×) MPH (0.60 mg/kg/day, b.d.) – 83 5–13 3 Core: not reported QoL: not reported AE: Stimulant Drug Side Effects Questionnaire: 17-item list Barkley, 1990 39 C (3×) MPH (0.80 mg/kg/day, b.d.) – 161 2.4–17.2 3 Core: CPRS-R: Hyperactivity Index; CTRS-R: Hyperactivity Index; CTRS-R: hyperactivity QoL: not reported AE: CPRS-R: psychosomatic; SERS (parents, teachers): number and severity of side-effects Fischer, 1991 54 C (3×) MPH (0.90 mg/kg/day, t.d.s.) – 234 5–15 4 Core: not reported QoL: not reported AE: BSEQ Ahmann, 1993 35 continued
TABLE 5 MPH medium dose (15–30 mg/day) versus placebo (cont’d) Study Design Intervention – N Age Duration Core outcomes (years) (weeks) C (3×) MPH [0.60 mg/kg/day (unclear), b.d.] – 12 6–10 3 Core: not reported QoL: not reported AE: Side Effects Questionnaire Fine, 1993 52 C (3×) MPH (16.2 mg/day, b.d.) – 31 5.4–9.9 6 Core: no hyp; IOWA CTRS: inattention/overactivity QoL: not reported AE: not reported Pelham, 1993 79 C (2×) MPH (22.3 mg/day, b.d.) – 114 5.6–11.9 6 Core: Abbreviated Conners’ Hyperactivity Questionnaire (parents and teachers); TOTS: hyperactivity (parents and teachers) QoL: no CGI AE: somatic complaints (parents); mood problems (parents); weight Klorman, 1994 68 P MPH (20 mg/day, b.d.) – 32 6–13 4 Core: data presented in graphs cannot be extracted QoL: not reported AE: SSERS (modified version): frequency and severity (parents, psychiatrist) Buitelaar, 1996 44 © Queen’s Printer and Controller of HMSO 2006. All rights reserved. C (4×) MPH (17.6 mg/day, b.d.) – 25 6–12 4 Core: CPRS – hyperactivity index; ACTeRS: hyperactivity MPH (26.4 mg/day, t.d.s.) – 25 QoL: not reported MPH (17.6–26.4 mg/day 2 or 3× titrated) – 25 AE: SSERS (parents); weight Stein, 1996 91 Health Technology Assessment 2006; Vol. 10: No. 23 C (3×) MPH (0.60 mg/kg/day, b.d.) – 50 6.1–18.2 4 Core: CPRS: Hyperactivity Index; CTRS: Hyperactivity Index QoL: not reported AE: not reported Hoeppner, 1997 61 C (3×) MPH (25–30 mg/day, max. 3×) – 11 4–5.1 3 Core: CTRS: Hyperactivity Index; CTRS: hyperactivity QoL: not reported AE: Side Effects Checklist (teachers, parents); mean severity rating 0–6 Handen, 1999 60 C (4×) MPH (0.60 mg/kg/day, b.d.) – 22 7–13 6 Core: no hyp; IOWA CTRS: inattention/overactivity. QoL: not reported AE: SSERS Kolko, 1999 69 C (4×) MPH (20 mg/day, b.d.) – 42 5–17 4 Core: no hyp; ASQ (parents) (teachers); ARS (parent) MPH (30 mg/day, b.d.) – 42 QoL: no CGI; composite ratings (clinician) AE: SE/BMS (parents) Manos, 1999 72 continued 25
Page 1 and 2: A systematic review and economic mo
Page 3 and 4: A systematic review and economic mo
Page 5 and 6: Objectives: To assess the clinical
Page 7 and 8: Glossary and list of abbreviations
Page 9 and 10: Glossary Adverse effect An abnormal
Page 11 and 12: Glossary continued effects. Sometim
Page 13 and 14: Glossary continued point between tw
Page 15 and 16: Background Attention deficit hypera
Page 17 and 18: mean differences with 95% confidenc
Page 19: This review examines the clinical a
Page 22 and 23: 4 Background E. Symptoms should not
Page 24 and 25: 6 Background Concerta XL Concerta X
Page 26 and 27: 8 Methods for reviewing effectivene
Page 28 and 29: 10 Methods for reviewing effectiven
Page 31 and 32: Quantity and quality of research av
Page 33 and 34: TABLE 1 The quality of included stu
Page 35 and 36: TABLE 2 An overview of trials inclu
Page 37 and 38: TABLE 2 An overview of trials inclu
Page 39 and 40: TABLE 3 MPH low dose (≤15 mg/day)
Page 41: Quality of life Only one of the 12
Page 45 and 46: Hyperactivity All nine studies that
Page 47 and 48: TABLE 6 Results for hyperactivity [
Page 49 and 50: Study Parallel trials Buitelaar 199
Page 51 and 52: TABLE 8 Results for hyperactivity [
Page 53 and 54: Study Parallel trials Gittelman-Kle
Page 55 and 56: TABLE 11 MPH high dose (>30 mg/day)
Page 57 and 58: TABLE 14 ER-MPH medium dose (20-40
Page 59 and 60: Study Crossover trials Stein 2003 S
Page 61 and 62: TABLE 19 Results for hyperactivity
Page 63 and 64: TABLE 22 MPH low dose (≤ 15 mg/da
Page 65 and 66: TABLE 24 MPH medium dose (15-30 mg/
Page 67 and 68: assessed by parents and teachers. I
Page 71 and 72: TABLE 30 DEX medium dose (10-20 mg/
Page 75 and 76: TABLE 38 DEX medium dose (10-20 mg/
Page 77 and 78: TABLE 41 DEX-SR plus non-drug inter
Page 79 and 80: Study Michelson 2001 [0.5] Michelso
Page 81 and 82: Hyperactivity Five trials (publishe
Page 83 and 84: TABLE 47 IR-MPH low-dose (≤ 15 mg
Page 85 and 86: STP. 77,78 Neither examined hyperac
Page 87 and 88: Adverse events No significant diffe
Page 89 and 90: did report that there were no signi
Page 91 and 92: Summary The one study in this categ
Page 93 and 94:
showed persisting significant super
Page 95 and 96:
easily rectified with dosage adjust
Page 97 and 98:
Aim The aim of this chapter is to r
Page 99 and 100:
only level of social disability tha
Page 101 and 102:
did not include a ‘global’ HRQo
Page 103 and 104:
might decrease but costs would be e
Page 105 and 106:
1st line pharmacotherapy Response,
Page 107 and 108:
TABLE 70 Data for weighted average
Page 109 and 110:
The probabilistic results were used
Page 111 and 112:
The review also uncovered a mis-ref
Page 113 and 114:
TABLE 77 Results of sensitivity ana
Page 115 and 116:
TABLE 80 Response a rates (%) estim
Page 117 and 118:
TABLE 82 Drug costs used in the cos
Page 119 and 120:
The review of the economic evidence
Page 121 and 122:
Extrapolation A secondary analysis
Page 123 and 124:
economic model rests on the assumpt
Page 125 and 126:
TABLE 87 Data used in calculating w
Page 127 and 128:
not fully probabilistic. The averag
Page 129 and 130:
Probability cost-effective 1.0 0.9
Page 131 and 132:
TABLE 93 Results of sensitivity ana
Page 133 and 134:
Base case model Responder to MPH Re
Page 135 and 136:
TABLE 96 Results of the sensitivity
Page 137 and 138:
The same method for synthesising th
Page 139 and 140:
TABLE 103 Results of the economic m
Page 141:
of the 64 identified in the clinica
Page 144 and 145:
126 Discussion impact of active dru
Page 147:
MPH, DEX and ATX improve hyperactiv
Page 151 and 152:
1. National Institute for Clinical
Page 153 and 154:
tutoring on the behavior and achiev
Page 155 and 156:
91. Stein MA, Blondis TA, Schnitzle
Page 157 and 158:
140. Hill P, Taylor E. An auditable
Page 159 and 160:
189. Francis S, Fine J, Tannock R.
Page 161 and 162:
235. Rhodes SM, Coghill DR, Matthew
Page 163 and 164:
hyperactive boys: comparative and c
Page 165 and 166:
This version of HTA monograph volum
Page 167 and 168:
380 Health Technology Assessment Pr
Page 169:
382 Health Technology Assessment Pr
show all

A systematic review and economic model of the effectiveness and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?